Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by WD Rutherford LLC

WD Rutherford LLC decreased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% during the 4th quarter, HoldingsChannel reports. The firm owned 8,401 shares of the medical equipment provider’s stock after selling 50 shares during the period. Intuitive Surgical comprises 1.7% of WD Rutherford LLC’s holdings, making the stock its 29th largest position. WD Rutherford LLC’s holdings in Intuitive Surgical were worth $2,834,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Baystate Wealth Management LLC boosted its holdings in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 45 shares during the period. MCF Advisors LLC boosted its stake in Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares during the period. Atticus Wealth Management LLC increased its stake in shares of Intuitive Surgical by 85.4% in the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 41 shares during the period. OFI Invest Asset Management bought a new stake in shares of Intuitive Surgical during the third quarter valued at approximately $25,000. Finally, Headinvest LLC bought a new position in Intuitive Surgical in the 3rd quarter worth approximately $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 249,418 shares of company stock worth $96,300,959. Insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ISRG. Stifel Nicolaus boosted their price target on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Truist Financial upped their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Piper Sandler raised their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Robert W. Baird cut their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Finally, Mizuho lifted their price target on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Stock Up 0.6 %

Shares of NASDAQ:ISRG opened at $375.33 on Friday. The company has a market cap of $133.13 billion, a P/E ratio of 67.75, a price-to-earnings-growth ratio of 4.82 and a beta of 1.36. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The company’s fifty day moving average is $386.19 and its two-hundred day moving average is $345.95.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the business posted $1.00 EPS. Equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.